BioCentury | Dec 1, 2020

Viracta to start pivotal trial as public company following Sunesis merger, private placement

An investor syndicate is backing Viracta with $105 million in fresh capital as the biotech goes public via a reverse merger and plans a pivotal trial of its lead therapy targeting EBV-positive lymphomas. By merging...
BioCentury | Nov 23, 2020
Emerging Company Profile

SV Health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”  SV’s Houman Ashrafian...
BioCentury | Nov 20, 2020
Translation in Brief

Long-term gene therapy study in dogs with hemophilia A; plus a comparison of HBV vaccine adjuvants and mAb that alleviates chemotherapy side effects

Long-term study of AAV gene therapy in dogs finds genome integration, clonal expansionA team led by University of Pennsylvania scientists showed in Nature Biotechnology that adeno-associated viral (AAV8 or AAV9) gene therapy corrected factor VIII...
BioCentury | Nov 20, 2020

SR One’s newfound freedom allows firm to increase focus on company creation

SR One’s spinout from GSK gives the newly independent VC the ability to scale up what has been a top-tier investment firm over the past decade, along with the freedom to take larger stakes...
BioCentury | Nov 19, 2020
Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12 therapy and highlight the ability of its exosome-based approach to extend retention in the tumor microenvironment. Codiak BioSciences Inc. (NASDAQ:CDAK) uses...
BioCentury | Nov 3, 2020

Data Byte: NK cell therapies draw slew of partnerships in 2020

Biopharma companies have signed at least 15 partnerships year to date focused on NK cell therapies, the modality that led to Kiadis’ €308 million ($358 million) acquisition by Sanofi on Monday.  Sanofi (Euronext:SAN; NASDAQ:SNY) joines Gilead Sciences Inc....
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).  Rare disease play X4 Pharmaceuticals Inc. (NASDAQ:XFOR) appointed...
BioCentury | Nov 2, 2020

Realignment around acquired NK assets primed Kiadis for €308M Sanofi buyout

A modestly-priced acquisition of an NK cell platform company in spring 2019 set up Kiadis for a premium takeout by its partner Sanofi, even after the Dutch biotech discontinued its lead T cell program late...
BioCentury | Oct 20, 2020

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) to identify drug candidates...
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

Genetic modifier company Maze Therapeutics has hired Sarah Noonberg as CMO. Noonberg was CMO of Nohla Therapeutics Inc. Maze debuted in February 2019 with a $191 million venture round led by Third Rock Ventures and...
Items per page:
1 - 10 of 880